

Ref: FOI/GS/ID 7884

**Please reply to:**  
FOI Administrator  
Trust Management  
Maidstone Hospital  
Hermitage Lane  
Maidstone, Kent  
ME16 9QQ  
Email: [mtw-tr.foiadmin@nhs.net](mailto:mtw-tr.foiadmin@nhs.net)  
[www.mtw.nhs.uk](http://www.mtw.nhs.uk)

29 December 2022

## **Freedom of Information Act 2000**

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Nivolumab

*You asked:*

*Q1. In the last 3 months, how many patients have been initiated\* on the following agents for the treatment of melanoma?*

- a. Nivolumab (monotherapy)*
- b. Nivolumab AND Ipilimumab (combination)*

*\*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.*

*Q2. In the last 3 months, how many patients have been initiated\* on the following agents for the treatment of Renal Cell Carcinoma?*

- a. Nivolumab (monotherapy)*
- b. Nivolumab + Ipilimumab*
- c. Nivolumab + Cabozantinib*
- d. Avelumab + Axitinib*

*\*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.*

*Q3. In the past 3 months, how many patients have been initiated\* on the following agents for the treatment of upper gastrointestinal cancer (oesophagael cancer, gastric cancer and gastro-oesophageal junction cancer)?*

- a. Nivolumab*
- b. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)*

*\*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.*

Trust response:

Answers below looking at the period 1/9/2022-30/11/2022

Q1.

a. 0

b. 3

Q2.

a. 0

b. 0

c. 0

d. 0

Q3.

a. 0

b. 2